

AWARD NUMBER: **W81XWH-18-1-0716**

TITLE:

Gender differences in complement-mediated reperfusion injury

PRINCIPAL INVESTIGATOR:

Sherry D Fleming

CONTRACTING ORGANIZATION:

Kansas State University, Manhattan, KS

REPORT DATE: **October 2021**

TYPE OF REPORT: **Annual Report**

PREPARED FOR: **U.S. Army Medical Research and Development Command**

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: **Approved for Public Release;
Distribution Unlimited**

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2021		2. REPORT TYPE Annual		3. DATES COVERED 30Sep2020-29Sep2021	
4. TITLE AND SUBTITLE Gender differences in complement-mediated reperfusion injury				5a. CONTRACT NUMBER W81XWH-18-1-0716	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Sherry D Fleming E-Mail:sdflemin@ksu.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Kansas State University, 2 Fairchild Hall Manhattan, KANSAS 66506				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT With increased female soldiers being exposed to combat, the number of women wounded or injured also increases. However, the rate of female combat deaths and extremity or abdominal injuries is significantly higher than within the male population. Thus, understanding mechanistic and treatment differences between men and women is critical. The mechanisms of excessive inflammation in intestinal ischemia/reperfusion injury includes complement activation and neutrophil infiltration in male mice. Due to females experiencing different symptoms, we hypothesized that the mechanisms of inflammation would differ. Our current data demonstrate that female mice use different complement initiators and regulators resulting in distinct kinetics of complement activation as well as inflammatory cell infiltration. Together, these data suggest that sex specific treatments may be required for ischemic events.					
15. SUBJECT TERMS None listed.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 30	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	3
2. Keywords	3
3. Accomplishments	3
4. Impact	11
5. Changes/Problems	12
6. Products	13
7. Participants & Other Collaborating Organizations	15
8. Special Reporting Requirements	17
9. Appendices	17

1. INTRODUCTION:

With increased female soldiers being exposed to combat, the number of women wounded or injured also increased but the rate of female combat deaths and extremity or abdominal injuries remains significantly higher than within the male population. Thus, understanding mechanistic and treatment differences between men and women is critical. We proposed to examine the mechanisms of inflammation in intestinal ischemia/reperfusion of male and female mice. We will examine intestinal deposition of complement initiators and regulators as well as neutrophilic inflammatory responses in both sexes.

2. KEYWORDS:

Complement activation, sex, gender, eicosanoid, inflammation, complement regulators, leukotrienes, prostaglandins

3. ACCOMPLISHMENTS:

What were the major goals of the project?

Specific Aim 1 Determine if complement initiation differs between sexes	Timeline	KSU	Percent Complete
Major Task 1 : Establish animal colonies	Months		
Subtask 1: IACUC and ACURO Approvals	1-3	Dr. Fleming	100%
Obtain and breed specific knock out mice	3-6	Dr. Fleming	100%
Milestone Achieved: HRPO/ACURO Approval	6	Dr. Fleming	100%
Major Task 2: Determine specific complement initiation pathway and regulators utilized in females			

Subtask 1 Time course and C1q ^{-/-} and MBL ^{-/-} ischemia/reperfusion (IR) surgeries will be performed and injury and inflammation analyzed. 10 mice per group, with the following groups for both male and female mice: Time course study: wildtype (C57Bl/6 mice) Sham and 30 min ischemia and reperfusion (IR), for 0.5, 1, 2, or 4 hr reperfusion, C1q ^{-/-} Sham, C1q ischemia/reperfusion (IR), MBL (mannose binding lectin) ^{-/-} Sham, MBL ^{-/-} IR. The deficient mice will use the optimal reperfusion time point determined in the time course. Injury will be determined histologically. Inflammatory assays will include complement proteins (C3 and C5) expression determined by PCR and western blot) and activation (plasma C3a/C5a), eicosanoids (leukotrienes and prostaglandins) and cytokines such as IL-1, IL-6, IL-12 and IL-10.	7-12	Dr. Fleming (total 180 animals)	100%
Subtask 2 Specific immunohistochemistry (IHC) studies will be performed for C3, C1q, C4, Factor B, Membrane attack complex, IgM and β 2-glycoprotein I (β 2-GPI)	8- 15	Dr. Fleming	100%
<i>Milestone(s) Achieved: Female complement initiation pathways determined and manuscript submitted if applicable</i>	12-15	Dr. Fleming	100%
Major Task 3: Determine role of estrogen in complement initiation			Percent Complete
Subtask 1: Perform estrogen receptor (ER) ^{-/-} IR surgeries and analyze injury; Groups will include ER ^{-/-} + Saline Sham, ER ^{-/-} + Saline IR, ER ^{-/-} + estrogen Sham and ER ^{-/-} + estrogen IR, Wildtype Sham and wildtype IR mice.	10-13	Dr. Fleming (total 160 animals)	100%
Subtask 2: Perform inflammatory and IHC studies. Inflammatory assays will include complement proteins (C3 and C5) expression determined by PCR and western blot) and activation (plasma C3a/C5a), eicosanoids (leukotrienes and prostaglandins) and cytokines such as IL-1, IL-6, IL-12 and IL-10. IHC will include C3, C1q, C4, Factor B, Membrane attack complex, IgM and β 2- glycoprotein I (β 2-GPI) as appropriate.	11-16	Dr. Fleming	100%
Milestone(s) Achieved: Role of estrogen receptors in complement initiation determined and manuscript submitted if applicable	14-24	Dr. Fleming	85%

Specific Aim 2: Determine role of complement regulators in female response to IR			
Major Task 4: Determine role of complement regulators			Percent Complete
Subtask 1: Analyze tissues from time course Aim 1 for complement inhibitors and obtain inhibitors (recombinant Decay accelerating factor (rDAF), (Complement receptor 2- Factor H (CR2-FH), Complement related receptor Y (CRRY), murine Factor H).	8-12	Dr. Fleming	100%
Subtask 2: Perform IR surgeries with complement inhibitors. Male and female C57Bl/6 mice will be randomized and blinded into the following groups: Wildtype C57BL/6 + saline IR and Wildtype C57BL/6 + saline Sham, C57BL/6 + rDAF Sham, C57BL/6 + rDAF IR, C57BL/6 + CR2-FH Sham, C57BL/6 + CR2-FH IR. C57BL/6 + CRRY Sham, C57BL/6 + CRRY IR, C57Bl/6 +FH Sham and C57Bl6 + FH IR.	12-17	Dr. Fleming (total 100 animas)	100%
Subtask 3: Analyze injury and inflammation. Injury will be analyzed histologically. Inflammatory assays will include complement proteins (C3 and C5) expression determined by PCR and western blot) and activation (plasma C3a/C5a), eicosanoids (leukotrienes and prostaglandins) and cytokines such as IL-1, IL- 6, IL-12 and IL-10. IHC will include C3, C1q, C4, Factor B, Membrane attack complex, IgM and β 2-glycoprotein I (β 2-GPI) as appropriate.	15-20	Dr. Fleming	90%
Milestone(s) Achieved: Female complement inhibition pathways determined and manuscript submitted if applicable	20-24	Dr. Fleming	95%
Major Task 5: Determine the role of estrogen on complement regulation			Percent Complete
Subtask 1: Analyze tissues from Aim 2, task 3 for complement regulatory molecules	10-13	Dr. Fleming	100%
Subtask 2: Perform inflammatory and IHC studies	12-17	Dr. Fleming	100%
Milestone(s) Achieved: Role of estrogen receptors in complement regulation determined and manuscript submitted if applicable	18-24	Dr. Fleming	90%

Specific Aim 3: Determine similarities in male and female neoantigens and naturally occurring antibodies			
Major Task 6: Determine female IR-induced neoantigens			Percent Complete
Subtask 1: Determine IR-induced expression of β 2-GPI, NMM, and Annexin IV by IHC and western blot (tissues from time course mice (Aim 1, Task 1))	15-16	Dr. Fleming	75%
Subtask 2: Purify β 2-GPI from mouse serum and analyze from wildtype female serum using ELISA or immunoprecipitation.	20-25	Dr. Fleming (total 50 animals)	10%
Subtask 3: Perform IR with injury and inflammation determinations on wildtype mice with neoantigen inhibitors. Male and female mice will be subjected to Sham + peptide, Sham + saline, IR + saline, IR + β 2-GPI peptides: p296c-s, RD-p9, IR + control peptides.	25-32	Dr. Fleming (total 120 animals)	
Milestone(s) Achieved: Differences in neoantigen expression in females identified and manuscript submitted if applicable	32-36	Dr. Fleming	
Major Task 7: Determine natural antibody specificities required for IR-injury in females			Percent Complete
Subtask 1: Purify antibodies from mouse sera and deplete specific antibodies	20-25	Dr. Fleming (total 50 animals)	80%
Subtask 2: Perform IR on male and female Rag-1 ^{-/-} mice receiving appropriate antibodies. Sham or IR+ anti-non-muscle myosin, IR + anti-annexin IV, IR + β 2-GPI.	25-30	Dr. Fleming (total 120 animals)	80%
Subtask 3: Analyze injury and inflammation. Eicosanoid and cytokine ELISAs and complement activation products will be determined	30-34	Dr. Fleming	60%
Milestone(s) Achieved: Differences in natural antibody specificities identified and manuscript submitted if applicable	34-36	Dr. Fleming	


What was accomplished under these goals?

Major Tasks 1 and 2 are completed and resulted in a second manuscript within the last year. The manuscript demonstrated males use both C1q and MBL pathways, while females tend to depend on lectin pathway during intestinal IR. The published

manuscript is attached.

Major Tasks 3 and 5: To determine the role of estrogen in complement initiation and regulation, we performed IR surgeries on ER2^{-/-} and ovariectomized mice for Subtasks 1 and 2 of each major task. The inflammatory and IHC studies are almost completed. A manuscript is in progress and should be submitted in the next year. Specific findings include subjecting ER2^{-/-} mice to IR and evaluating injury and eicosanoid production (Fig. 1 A). Based on an initial time course, these mice were subjected to 1 hr reperfusion as that demonstrated maximal injury. Similar to our previous published manuscript (Wu et al), male and female mice had similar injury at 1 hr but the lack of estrogen receptor 2 for signaling, resulted in significantly increased injury and PGE2 but did not alter LTB4 secretion. As a second method of examining the role of estrogen in the IR-induced damage, young female mice were ovariectomized (OVX) at ~ 3

mo prior to subjecting them to IR with 2 hr reperfusion based on the initial time course study. As indicated in Figure 1B, at 2 hr post reperfusion the OVX mice sustained injury that was not significantly different from male wildtype mice ($p=0.236$) but trended towards being significantly different from male wildtype mice ($p=0.087$). The PGE2 and LTB4 analysis is in progress. Together, these data suggest that estrogen and estrogen signaling plays a role in some but not all



aspects of IR pathology. Future studies will add additional animals to the OVX group to determine significance.

We initiated studies to examine complement activation and inhibition with C5a production in plasma collected with Fut-175 to inhibit ex vivo complement activation. Surprisingly, females produced significantly less C5a in Sham treated mice (Figure 2). Although not significant, females produce less C5a in IR treated mice after 2 hr reperfusion IR treated mice (N=3). Future studies will increase the number of animals for these data and extend the data by examining the complement initiators and inhibitors by IHC and RT-PCR.

Major Task 4: We used two methods to examine the role of complement regulators, DAF, FH and CRRY in complement mediated IR-induced tissue damage. The first method utilized DAF or FH deficient mice (Fig. 3). The injury score of DAF^{-/-} animals was not significantly different from wildtype (B6 mice) probably due to redundancy in C3 complement inhibitors (Fig. 3 top). In contrast, the FH deficient mice sustained no intestinal injury and the sera contained significantly reduced C3 (Fig. 3 bottom) indicating a consumption of C3 due to a lack of Factor H. Thus, neither of these models were appropriate for continued studies.

To continue the investigation, we used our alternative of treating with targeted complement inhibitors, CR2-FH and C2-CRRY. CR2 targets the Factor H to C3b deposition and C2 targets the CRRY to damaged tissue. At published doses, both inhibitors attenuated injury in both sexes as expected (Fig. 4). However, in a lower dose of C2-CRRY, we found that the female injury returned to normal while the lower dose still inhibited the male injury. This indicates that the male injury is




Figure 2. After Sham or IR treatment, female mice (yellow bars) secrete less C5a compared to similarly treated male (purple bars) mice (N=3).





Figure 3:Factor H (FH) and DAF (CD55) deficient mice were subjected to 2 hr IR and injury score and sera C3 levels were determined. N=3-7 and * indicates significant difference from corresponding male (p<0.05).

Figure. 4. Targeted therapeutics attenuate IR-induced injury in each sex differently. Mice were subjected to IR and CR2-FH or C2-CRRY were administered i.vi 5 min prior to reperfusion. N=3-5, * indicates significant difference from male IR.

more susceptible to the inhibitor. Similarly, a high dose of CR2-FH attenuates injury in both sexes and a lower dose attenuates the male injury but not the female injury. Together, the data suggest that complement inhibitors FH and CRRY are more critical to male injury than female for injury. Additional studies are ongoing to examine the inflammatory response. We expect a publication to be submitted within the next 6 months.

Major tasks 6 and 7: Examining the specific neoantigens and natural antibodies are in progress. Preliminary studies demonstrate that intestines of male mice express extracellular annexin IV at earlier time points than female mice (Figure 5, top). In contrast, intestines from female mice appear to express more extracellular Non-muscle myosin than male mice (Figure 5, bottom). These studies will be expanded to complete time courses and corresponding antibodies determined within the next year.

What opportunities for training and professional development has the project provided?



Both post-docs have successfully obtained in senior position in either academia or industry. Ms. Rowe, technician, obtained authorship on an additional manuscript and is building her CV.

How were the results disseminated to communities of interest?

Publication of a manuscript in Frontiers in Immunology (see attached). I presented our studies to the local American Legion post as well as to undergraduates looking for research opportunities. They were very interested.

What do you plan to do during the next reporting period to accomplish the goals?

We will complete the manuscripts and continue with Major tasks 6 and 7.

4. IMPACT:

What was the impact on the development of the principal discipline(s) of the project?

Identifying mechanistic sex differences may provide for more appropriate treatment of each sex in the future.

What was the impact on other disciplines?

Nothing to Report

What was the impact on technology transfer?

Nothing to Report

What was the impact on society beyond science and technology?

Nothing to Report

5. CHANGES/PROBLEMS:

Nothing to Report

Actual or anticipated problems or delays and actions or plans to resolve them

Covid-19 has delayed our progress. We had limited lab function from Mar 20- present. In addition, due to Covid-19, both post-docs have left. Data was analyzed and manuscripts were written and submitted but actual lab work has been limited.

Changes that had a significant impact on expenditures

Post-doc Dr. Miaomiao Wu, acquired a faculty position in Sept 2020 and post-doc Pavitra Natarajan left in May 2021. At this time, we do not have a post-doc. This saved money but also delayed the project. However, the PI has performed the surgeries and is writing manuscripts.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Significant changes in use or care of human subjects

Nothing to Report

Significant changes in use or care of vertebrate animals

Nothing to Report

Significant changes in use of biohazards and/or select agents

Nothing to Report

6. PRODUCTS:

- **Publications, conference papers, and presentations**

Journal publications.

Wu M. Wu M, Rowe JM, Fleming SD. 2021. Complement Initiation Varies by Sex in Intestinal Ischemia Reperfusion Injury. *Frontiers in Immunol* 12:649882 DOI: 10.3389/fimmu.2021.649882 **Published**
Acknowledgement of federal support: Yes.

Books or other non-periodical, one-time publications.

Nothing to Report

Other publications, conference papers and presentations.

Nothing to Report

- **Website(s) or other Internet site(s)**

Nothing to Report

- **Technologies or techniques**

Nothing to Report

- **Inventions, patent applications, and/or licenses**

Nothing to Report

- **Other Products**

Nothing to Report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Name: Sherry Fleming

Project Role: PI

Researcher Identifier <https://orcid.org/0000-0001-5385-7233>

Nearest person month worked: 1 mo

Contribution to Project: Dr. Fleming has coordinated the approval of the regulatory animal protocols and ordering of animals and the appropriate animal surgeries.

Name: Jennifer Rowe

Project Role: Animal Technician

Researcher Identifier; <https://orcid.org/0000-0001-6812-4315>

Nearest person month worked: 12 mo

Contribution to Project: Ms Rowe has coordinated the ordering and breeding of the specific mice. In addition, she has performed the animal surgeries.

There is no longer a post-doc available to work on the project.

What other organizations were involved as partners?

Nothing to Report

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS:

QUAD CHARTS:

9. APPENDICES:

Appendix 1: Published manuscript



Complement Initiation Varies by Sex in Intestinal Ischemia Reperfusion Injury

Miaomiao Wu^{1,2}, Jennifer M. Rowe² and Sherry D. Fleming^{2*}

¹ Animal Nutritional Genome and Germplasm Innovation Research Center, College of Animal Science and Technology, Hunan Agricultural University, Changsha, China, ² Division of Biology, Kansas State University, Manhattan, KS, United States

OPEN ACCESS

Edited by:

Nicole Thielens,
UMR5075 Institut de Biologie
Structurale (IBS), France

Reviewed by:

Kazuo Takahashi,
Massachusetts General Hospital and
Harvard Medical School, United States
Trent M. Woodruff,
The University of Queensland,
Australia

*Correspondence:

Sherry D. Fleming
sdflem@ksu.edu

Specialty section:

This article was submitted to
Molecular Innate Immunity,
a section of the journal
Frontiers in Immunology

Received: 05 January 2021

Accepted: 08 March 2021

Published: 01 April 2021

Citation:

Wu M, Rowe JM and Fleming SD
(2021) Complement Initiation
Varies by Sex in Intestinal
Ischemia Reperfusion Injury.
Front. Immunol. 12:649882.
doi: 10.3389/fimmu.2021.649882

Intestinal ischemia reperfusion (IR)-induced tissue injury represents an acute inflammatory response with significant morbidity and mortality. The mechanism of IR-induced injury is not fully elucidated, but recent studies suggest a critical role for complement activation and for differences between sexes. To test the hypothesis that complement initiation differs by sex in intestinal IR, we performed intestinal IR on male and female WT C57B6L/, C1q^{-/-}, MBL^{-/-}, or properdin (P)^{-/-} mice. Intestinal injury, C3b and C5a production and *ex vivo* secretions were analyzed. Initial studies demonstrated a difference in complement mRNA and protein in male and female WT mice. In response to IR, male C1q^{-/-}, MBL^{-/-} and P^{-/-} deficient mice sustained less injury than male WT mice. In contrast, only female MBL^{-/-} mice sustained significantly less injury than female wildtype mice. Importantly, wildtype, C1q^{-/-} and P^{-/-} female mice sustained significant less injury than the corresponding male mice. In addition, both C1q and MBL expression and deposition increased in WT male mice, while only elevated MBL expression and deposition occurred in WT female mice. These data suggested that males use both C1q and MBL pathways, while females tend to depend on lectin pathway during intestinal IR. Females produced significantly less serum C5a in MBL^{-/-} and P^{-/-} mice. Our findings suggested that complement activation plays a critical role in intestinal IR in a sex-dependent manner.

Keywords: LTB₄, PGE₂, mucosal injury score, MBL, properdin, sex, inflammation, C1q

INTRODUCTION

Ischemia reperfusion (IR) stems from the interruption of organ blood flow and its subsequent restoration and contributes to pathology in a wide range of clinical conditions, ranging from hemorrhagic shock, stroke, myocardial infarction, and early organ transplant rejection (1–5). These diseases are major causes of disability and even mortality. While not as common, acute mesenteric ischemia represents a potentially fatal vascular problem with an overall mortality rate of 70% to 90% (6, 7). It is becoming increasingly appreciated that gender differences exist in several models of IR, such as kidney (8), myocardial (9), hemorrhage (10), and intestine (11). After cardiac or brain ischemic events, females sustain less tissue injury, but remain hospitalized longer with higher in-

Abbreviations: IR, Ischemia reperfusion; LTB₄, leukotriene B₄; PGE₂, prostaglandins E₂; SMI, mucosal injury score; TMB, 3,3',5,5'-tetramethylbenzidine.

hospital mortality (12–15). Importantly, after heart attacks or strokes, more females are permanently disabled than males (16). Furthermore, whole genome RNA-seq analysis also showed sexual dimorphism in transcriptional response to myocardial ischemia (17).

Similar to clinical studies, female mice sustain reduced and delayed intestinal damage in multiple forms of IR and hemorrhage (18–20). Previous studies suggested that the damaging inflammatory response consists of both neutrophil and complement activation (21–23). Many studies demonstrated that arachidonic acid metabolism to eicosanoid production is critical for IR-induced intestinal damage and prostaglandins E₂ (PGE₂) was required for damage in male mice (22). However, a recent study demonstrated that intestines from female mice secrete potent chemo-attractants, the eicosanoid leukotriene B₄ (LTB₄) and C5a from the complement cascade (24). Though previous studies suggested a sexual dimorphism in eicosanoid production, the IR-induced difference between sexes in complement activation is unclear.

The complement system consists of over 30 soluble and membrane bound proteins that protect the host from invading pathogens (25). Three distinct primary pathways initiate complement activation: the antibody-antigen-binding activates complement through C1q; mannose binding protein (MBP) binding to carbohydrate triggers the lectin complement pathway; and the alternative pathway involves cleavage of Factor B (FB) and stabilization by the plasma glycoprotein, properdin (25). Complement components are not only produced in the hepatocytes and white blood cells, but also are produced by many other cell types, including intestinal epithelial cells. Importantly, mice express two forms of MBL, MBL-A and MBL-C and the MBL^{-/-} mice in the current study are deficient in both forms (26, 27). MBL-A is an acute phase protein highly expressed by the liver and the sera with maximal expression at ~30 hr post-lipopolysaccharide exposure (28, 29). Recent data suggests that the colon expresses MBL-A in response to chronic inflammation or infection (30). In contrast, the intestinal epithelial cells specifically express MBL-C (29, 31).

Recent studies demonstrated that the complement system has a central role in orchestrating inflammatory responses and IR-induced tissue injury (32) of multiple organs, including the intestine (7), kidneys (33), brain (34), and heart (35), of humans and animals (36). Previous studies characterized the reperfusion inflammatory response after intestinal ischemia by deposition of IgM and C3 in ischemic tissues (1, 37–39). Mice deficient in multiple complement components sustain reduced renal and/or cerebral IR induced injury to varying degrees (34, 40, 41). Importantly, IgM initiates intestinal, myocardial, and cerebral IR injury (38, 42, 43). Thus, initiated by antibodies, mesenteric IR damage was alleviated in C2-, C3-, C4-, and MBL-deficient mice (3, 7, 44).

The majority of studies described above used male mice. Using *ex vivo* assays, C3 activation was similar in C57B6L and Balb/c male and female mice (45). However, the terminal pathway from C5b to C9 was not as robust in females compared with male mice indicating sex plays an important role in IR-induced complement

activation. However, the differences *in vivo* remain unclear. Sexual dimorphism in the complement system poses interesting questions for immune biology response. Interestingly, accumulated research supports the idea that sex impact the immune system significantly (46) and complement activity may differ by gender (45). We hypothesized that the initiation of complement pathways may differ between males and females.

MATERIALS AND METHODS

Mice

WT C57B/6 (# 000664), C1q deficient (C1q^{-/-}; # 031675) and MBL-1/2-deficient (MBL^{-/-}; #006122) mice were purchased from The Jackson Laboratory. The properdin deficient (P^{-/-}) mice were provided by Dr. Wenchao Song, University of Pennsylvania with NIH grant support RO1 AI085596. All complement deficient mice were on the C57B6L/background. All mice were bred and maintained in the Division of Biology at Kansas State University, Manhattan, KS with a 12-h light/12-h dark cycle with a standard diet. Sex and age-matched (8 to 10 weeks old) mice were selected for experiments. All studies were approved by the Institutional Animal Care and Use Committee at Kansas State University and conducted according to the Animal Welfare Act and other federal statutes and regulations concerning animals and experiments involving animals.

Treatment of Intestinal IR

The surgical protocol for intestinal IR was performed as previously described (22). Briefly, isoflurane (2–3% in oxygen) anesthetized mice were subjected to a midline laparotomy and administered buprenorphine (0.06 mg/kg) for pain relief per the institutional animal care and use committee requirement. After a 30 min equilibration period, a small, nontraumatic, vascular clamp (Roboz Surgical Instruments, cat. #RS-5420) was applied to the superior mesenteric artery and ischemia was visually confirmed by blanching of the mid-jejunum. After a 30 min ischemic phase, the clamp was removed and the intestine was allowed to reperfuse for 15, 30, 60, or 120 min in WT mice or 30, 60, or 120 min in mutant mice. Reperfusion was affirmed by observing the return of pinkish color to the intestine. Sham mice were subjected to the same surgical intervention but without occlusion. All procedures were performed with the mice breathing spontaneously and all mice were kept on a 37°C water-circulating heating pad to maintain body temperature. During the reperfusion period, mice were allowed to recover from anesthesia. Additional isoflurane was administered immediately prior to sacrifice. After sacrifice, serum and four sections of the mid-jejunum (2 cm each), beginning approximately 10 cm distal to the gastroduodenal junction, were harvested for histological evaluation, immunohistochemistry, RT-PCR, as well as eicosanoid and cytokine determination.

Histology and Immunohistochemistry

After euthanasia, 2 cm mid-jejunum specimens were immediately fixed in 10% neutral buffered formalin phosphate,

embedded in paraffin, cut transversely in 8 cm sections, transferred to positively charged slides, and stained with hematoxylin and eosin (H&E). The score of mucosal injury (SMI) for each slide was assessed using a six-tiered scale adapted from Chiu et al. (47), as described previously (48). Briefly, the average mucosal damage score of the mid-jejunum intestinal section was calculated by two well-trained observers unaware of the treatment. Each observer graded 90–150 villi on a scale of 0–6 with the following categories: Normal villi were assigned a score of zero; a score of 1 were assigned to villi with tip distortion; score 2 was assigned when Guggenheims' spaces were present; a score of 3 was assigned to villi with slight disruption of the epithelial cells; villi in which the lamina propria was exposed but intact were scored as 4; villi with exuding lamina propria were scored as 5; and score 6 was assigned when the villi displayed hemorrhage or denuded. Photomicrographs were acquired from H&E-stained slides by using a 20X, 0.5 Plan Fluor objective on Nikon 80i microscope. Images were obtained by utilizing a Nikon DS-5 M camera with the DS-L2 software at room temperature (Nikon).

Immediately after removal, additional 2 cm mid-jejunum sections were snap-frozen in optimal cutting temperature (O.C.T.) freezing medium (Fisher cat. # 23730571). Specimen were cut transversely in 8 cm sections and placed on the slides for immunohistochemistry, as described previously (23). Briefly, pre-chilled acetone fixed slides were incubated with 10% normal donkey sera in phosphate buffered saline (PBS) for 30 min at 37°C to block nonspecific binding. Following PBS washes, the intestinal sections were incubated with primary antibodies in the dark for 1 h at room temperature (RT) or overnight (O/N) at 4°C. Deposition of C3b, C1q, MBL-C, Factor B, and IgM deposition on the tissue sections was determined by staining with a purified rat-anti-mouse anti-C3b antibody (Hycult Biotechnologies, cat. # HM1065), anti-C1q or anti-MBL-C antibody (Cedarlane, cat. # CL7501AP and #CL7303AP, respectively), or rabbit-anti-mouse anti-Factor B antibody (Abcam, ab231072) followed by an Alexa Fluor 594 conjugated donkey-anti-rat IgG secondary antibody (Jackson ImmunoResearch, cat. # 712586153) or FITC-green conjugated donkey-anti-rabbit IgG secondary (Jackson ImmunoResearch, cat. # 711096152). Some tissues were stained with a primary rat-anti-mouse MBL-A (Invitrogen MA5-33352) followed by an Alexa Fluor 594 conjugated donkey-anti-rat IgG secondary antibody. The detection of IgM was performed similarly with the exception of using FITC AffiniPure Fragment goat-anti-mouse IgM antibody (Jackson ImmunoResearch, cat. # 115096075), and no secondary antibody was needed. All experiments contained serial sections stained with the appropriate isotype control antibodies. The slides were then mounted with ProLong Gold (Invitrogen, cat. # P10144). Images (4–8 images per section) were acquired by a well-trained blinded observer at RT by using a Nikon eclipse 80i microscope equipped with an Infinity 3S camera (Lumenera) and analyzed by utilizing Infinity Analysis software (Lumenera). All microphotographs were examined by Image J software (National Institutes of Health) using the fluorescent area fraction after

setting threshold for each experiment. The average of the isotype control was subtracted from each image. The average of 5 images from 3–4 animals per treatment group is analyzed and reported.

Ex Vivo Cytokine and Eicosanoid Determination

Mid-jejunal tissue *ex vivo* generation of eicosanoids and cytokines was determined by using an adapted procedure previously described (49). Briefly, immediately after collection, 2 cm mid-jejunum sections were minced, washed in pre-chilled Tyrode buffer (Sigma-Aldrich), and resuspended in 37°C freshly oxygenated Tyrode buffer. After 20 min incubation at 37°C, the supernatants and tissues were collected and stored at -80°C until assayed. The tissue protein content was detected by utilizing the bicinchoninic acid assay (Pierce, cat. # 23225) modified for use with microtiter plates. Bovine Serum Albumin (BSA) (Fisher Scientific, cat. # BP9703100) was used as a standard. The same intestinal tissue supernatants were used to determine concentrations of leukotriene B₄ (LTB₄) and prostaglandins E₂ (PGE₂) utilizing enzyme immunoassay kits (Cayman Chemical, cat. # 520111 and #500141, respectively). Supernatants generated for eicosanoids were also used to detect cytokine levels by using Milliplex MAP immunoassay kits (Millipore, custom kits) that were analyzed on a Milliplex Analyzer (Millipore). The concentrations of eicosanoid and cytokines were standardized per mg intestinal tissue protein per 20 min incubation period.

Serum IgM and C5a Determined by ELISA

Blood was collected from untreated or intestinal IR treated mice for IgM and C5a determination, respectively. Blood was allowed to clot for 30 min at room temperature and transferred to ice prior to serum collected by centrifugation for 20 min at approximately 1000×g. The mouse IgM (cat. # E99-101) and C5a (cat. # DY2150) were purchased from Bethyl Laboratories and R&D SYSTEMS, respectively. These assays were performed in accordance with the manufacturer's recommended procedures.

Quantitative Real-Time PCR

After euthanasia, one 2 cm mid-jejunal tissue approximately 10 cm distal to gastroduodenal junction was immediately snap frozen in liquid nitrogen and stored at 80°C until used for RNA analysis. Total RNA was isolated from intestine tissues using TRIzol reagent (Invitrogen, cat. # 15596018) and then treated with DNase I (Invitrogen, cat. #18047019) according to manufacturer's instructions. RNA quantity and quality were evaluated and measured by utilizing the Nano drop (Thermo Fisher Scientific). The reverse transcription was conducted at 25°C for 5 min, 42°C for 30 min, and 85°C for 5 min to get cDNA with 1 µg total RNA by using qScript first strand cDNA synthesis kit (Quanta Biosciences, cat. # 95047). Primers (Table 1) were designed with Primer3 according to the mouse gene sequence. Quantitative real-time PCR was conducted in a 25 µL total volume using an Applied Biosciences StepOnePlus thermocyclers (Thermo Fisher) with Perfecta SYBR Green Fastmix reagent (Quanta Biosciences, cat. # 95072-250). The PCR protocol is as follows: (i) pre-denaturation for 3 min at

TABLE 1 | Real Time PCR Primer Sequences.

Gene	Tm (°C) ^a	Sequence
<i>C1qa</i>	58	FWD: CAC CAA CCA GGA GAG TCC AT REV: ACC TGA AAG AGC CCC TTG TT
<i>MBL1</i>	60	FWD: AGGGTCACAAACCTGTGAGG REV: TTTGCCAGCTTCTCCTCAAT
<i>MBL2</i>	56	FWD: ATTGCCTACTTGGGCATCAC REV: ATCGTTCCACTTGCCATTTC
<i>Factor B</i>	58	FWD: CCA GCA TTT GGG TTT CAG TT REV: CAC ACC TCC AGA GGA GAA GC
Ribosomal 18s ^b	56	FWD: GGTTGATCCTGCCAGTAGC REV: GCGACCAAAGGAACCATAAC

^aAnnealing temperature.^bHouse-Keeping gene to which genes of interest were normalized.

95°C; (ii) an amplification and quantification program including 50 cycles of 10 sec at 95°C, 20 sec at Tm (**Table 1**), 10 sec at 72°C; (iii) melt curve start at 60°C, increasing by 0.5°C up to 95°C. After amplification, 18s rRNA was used as an internal control to normalize relative gene transcript levels, $\Delta\Delta C_t$ fold change relative to Sham-treated wildtype mice was determined.

Statistical Analysis

Data are presented as mean $\pm$ the standard error of the mean (SEM), and were statistically analyzed by 2-way ANOVA, 1-way ANOVA with Neman Keuls *post-hoc* test to compare between strains of mice with in the same sex, and unpaired t-test to determine differences between male and female of the same treatment. (Graph Pad/Instant Software Inc.). Differences between groups were considered significant when P value ≤ 0.05 .

RESULTS

Complement Initiation in Response to Intestinal IR Differs Between Sexes

Initiation of complement activation occurs by multiple pathways, which may lead to distinct complement activation in male vs female mice during intestinal IR. Initial studies examined complement initiation mRNA expression in intestines of wildtype male and female mice by RT-PCR of *C1qa*, *MBL1*,

MBL-2, and *Factor B*. The intestinal expression of *C1q* increased significantly in males at 15 min and remained elevated until 60 min IR (**Figure 1A**, blue bars), while female intestine expression of *C1q* remained similar to Sham levels for each of the time points examined (**Figure 1A**, yellow bars). *C1q* mRNA expression decreased at 120 min IR in both male and female intestines (**Figure 1A**). Intestinal expression of *MBL-A* mRNA was not different between sexes and in response to IR decreased at 60 min reperfusion (**Supplementary Figure 1**). In contrast, intestinal *MBL-C* expression did differ between sexes. In male intestines *MBL-C* was not elevated after IR, and significantly decreased from 60-120 min compared to intestines from Sham-treated males (**Figure 1B**, blue bars). However, the expression of intestinal *MBL-C* in females increased significantly from 30-60 min before decreasing significantly at 120 min IR (**Figure 1B**, yellow bars). Compared to males, female intestine express significantly higher level of *MBL-C* in Sham animals, and in IR from 30-120 min (**Figure 1B**). Both males and females had a significantly decreased level of intestinal *FB* mRNA at 120 min IR (**Figure 1C**). There were no significant differences in *FB* expression between male and female intestines, during the IR time course (**Figure 1C**).

To confirm the expression of complement initiators and major players in the complement pathways, we detected the intestinal deposition of *C1q*, *MBL* or *MBL-C*, and *FB* by immunohistochemistry. Similar to mRNA expression levels, *C1q* intestinal staining was slightly but not significantly increased in males at 30 min after ischemia and returned to Sham levels by 120 mins after ischemia (**Figure 2A** and data not shown). In contrast to *C1q*, minimal *MBL-A* or *MBL-C* staining was detected after 30 min of reperfusion (data not shown) but by 120 min, *MBL-C* accumulated on intestines of both sexes (**Figure 2B** and **Supplementary Figure 1**). These data correlate with previously reported intestinal expression of *MBL-C* but not *MBL-A* (29). Compared to the *MBL-C* staining, *MBL-A* staining was not increased compared to Sham treatment (**Supplementary Figure 1**). Although not significantly different, male intestines tended to have more - staining for *MBL-C* than females (**Figure 2B**). In addition, in both sexes antibodies directed against *FB* stained the intestines consistently after Sham or at any IR time points (**Figure 2C**).




FIGURE 1 | Intestinal IR-induced complement initiation transcription differs between sexes. C57B6L/J mice were subjected to Sham and IR treatment with 15, 30, 60, or 120 min reperfusion. Mid-jejunum of (A) *C1q*, (B) *MBL-C*, and (C) *Factor B*, RNA expression was determined by RT-PCR analysis. Samples were normalized to 18S followed by fold change compared to Sham treatment. *, indicates significant difference between IR treatment and Sham within the same sex ($P \leq 0.05$), as determined by 1-way ANOVA followed by Newman Keuls *post-hoc* test; Φ , indicates significant difference between sexes in the same time point and same treatment ($P \leq 0.05$), as determined by unpaired t-test. Each bar is representative of 7-12 mice per group.




FIGURE 2 | Intestine tissue C1q, MBL-C, Factor B, deposition differs between sexes. C57B6L/J mice were subjected to Sham and IR treatment with 30 or 120 min reperfusion. Intestinal sections were stained for **(A)** C1q, **(B)** MBL-C, **(C)** Factor B, by immunohistochemistry. Bar = 40 μ m. The image analyses for each animal were determined by digital densitometry recognition using computer-aided ImageJ (NIH). Microphotographs (200X) are representative of at least 3-4 mice stained in at least 3 independent experiments.

In response to IR, IgM was deposited in both males and females after 120 min reperfusion (**Figure 3A**). Intestinal C3b deposition was enhanced in both sexes by 60 min (data now shown) and 120 min post-ischemia (**Figure 3B**). Taken together, our data indicate that all three complement pathways play a role in both sexes after intestinal IR in wildtype mice. However, during reperfusion, intestines in males contained increased C1q and MBL-C proteins, while females contained MBL-C. The

amplification pathway as indicated by FB is important for IR-induced injury in both sexes of wildtype mice.

Complement Deficiency Protects Mice From Intestinal IR Injury in a Sex Dependent Manner

To understand the specific role of each initiation pathway intestinal IR-induced tissue damage, we subjected C1q^{-/-},




FIGURE 3 | Intestine tissue IgM, and C3b deposition after 2 h reperfusion differs between sexes. C57B6L/J mice were subjected to Sham and IR treatment with 30- or 120-min reperfusion. Intestinal sections from Sham or IR WT mice were stained for **(A)** IgM and **(B)** C3b by immunohistochemistry. Bar = 40 μ m. The image analyses for each animal were determined by digital densitometry recognition using computer-aided ImageJ (NIH). Microphotographs (200X) are representative of at least 3-4 mice stained in at least 3 independent experiments. *, indicates significant difference between IR treatment and Sham within the same sex (P ≤ 0.05), as determined by 1-way ANOVA followed by Newman Keuls *post-hoc* test; Φ, indicates significant difference between sexes in the same time point and same treatment (P ≤ 0.05), as determined by unpaired t-test.

MBL^{-/-}, and P^{-/-} male and female mice to Sham or 120 min mesenteric IR. As there was no significance among Sham treatment at different time points of the same sex of either C57B6L/(wildtype, WT) or knockout (KO) mice, injury scores and subsequent analyses were pooled by sex for Sham treatment only (**Supplementary Table 1**). Compared to Sham mice, intestinal damage increased significantly in both sexes in WT mice after 120 min of reperfusion (**Figures 4A, B**). In addition, both sexes of C1q^{-/-}, MBL^{-/-}, and P^{-/-} mice sustained increased tissue damage compared to the Pooled Sham animals. Compared to male WT after IR, intestinal injury was significantly reduced in all deficient mice (**Figure 4A**). In contrast, compared to the female WT after IR, intestinal injury in females was significantly decreased in only MBL^{-/-} (**Figure 4A**). However, a significant difference between sexes existed in all strains of animals. When comparing IR-induced damage in males and females, WT and P^{-/-} male mice sustained significantly more tissue injury than female mice. However, deletion of C1q resulted in significantly reduced intestinal damage in males, compared to similarly treated female mice (**Figure 4A**).

Using the same data, the injury score was analyzed as a percent protection. Analysis by 2-way ANOVA indicated that the interaction of sex with the strain was extremely significant (**Figure 4C**). Although the complement deficiency accounted for the majority of the variance, sex was also significantly different. In response to IR, all strains of complement deficient male mice were more protected than the wildtype, C57B6L/mice

(**Figure 4C**). However, wildtype female mice were protected ~55% compared to 25% protection in male C57B6L/mice. Although the complement deficient female mice were 60-80% protected, only the MBL^{-/-} females were statistically significant compared to the wildtype (**Figure 4C**).

These data suggest that males are protected with any of the examined complement deficiencies and sustained an intermediate amount of injury in the absence of properdin. In contrast, only MBL^{-/-} female mice are significantly more protected than the wildtype mice. However, the female wildtype mice are more protected than the male wildtype mice. Together with changes in deposition of C1q, MBL, and FB (**Figure 2**), these results indicate that all three complement pathways are required for inducing intestinal IR injury in male mice, while the lectin pathway is particularly critical for inducing tissue damage in females. Specifically, IR-induced tissue damage requires C1q in males more than females, MBL is critical for both sexes, and alternative pathway appears to amplify the injury during intestinal IR.

Depletion of MBL or Properdin Decreases Serum C5a Levels in Both Sexes Following Intestinal IR

As IgM deposition initiates complement activation in response to IR, we examined normal serum IgM to determine if sufficient IgM was available for complement activation. Although all three genetically modified strains of mice contained significantly less




FIGURE 4 | Intestinal IR-induced tissue damage was protected in complement deficient mice in a sex-dependent manner. C57B6L/J WT, C1q^{-/-}, MBL^{-/-}, and P^{-/-} mice were subjected to Sham and IR treatment with 120 min reperfusion and mid-jejunum sections H&E stained and scored for mucosal injury (75-150 villi per section). **(A)** Individual injury scores of Pooled Sham (Sham), or IR treated C1q^{-/-}, MBL^{-/-} or P^{-/-} male (blue bars) and female (yellow bars) mice are shown. **(B)** Representative microphotographs of H&E stained section (200x) of Sham or IR treated C1q^{-/-}, MBL^{-/-} or P^{-/-} male (blue outline) and female (yellow outline) mice are presented. Bar = 40 μm. **(C)** Percent protection was calculated by the following equation, (1-(Injury score/Max injury of 4.0)*100). * indicates significant difference between IR treatment and Sham within the same sex (P ≤ 0.05), as determined by 1-way ANOVA with Newman Keuls *post-hoc* test; Φ indicates significant difference between sexes in the same point same treatment (P ≤ 0.05), as determined by unpaired t-test; τ indicates significant difference between same sex IR compared to WT IR (P ≤ 0.05), as determined by 1-way ANOVA with Newman Keuls *post-hoc* test. Each bar is representative of 7-12 mice per group.




FIGURE 5 | MBL-C or Factor P deficiency decreases serum IgM, C3b and C5a levels in both sexes following intestinal IR. **(A)** Serum from untreated C57B6/J WT, C1q^{-/-}, MBL^{-/-}, and P^{-/-} male (blue) and female (yellow) mice was analyzed by ELISA for IgM. Sham treatment is indicated by light colors whereas IR is indicated by dark colors. Each bar represents 2-3 pools of 3-5 mice. **(B)** C3b deposition on intestines from male (blue) and female (yellow) C57B6/J WT, C1q^{-/-}, MBL^{-/-}, and P^{-/-} mice was examined after Sham and IR treatment with 120 min reperfusion. Each bar represents 3-4 animals in at least 3 independent experiments. **(C)** Serum C5a from C57B6/J WT, C1q^{-/-}, MBL^{-/-}, and P^{-/-} mice was determined after Sham and IR treatment with 120 min reperfusion. Sham treatment represents pooled analysis of all strains. Each bar is representative of 7-12 mice per group. Serum IgM and C5a were measured with sandwich ELISA. C3b deposition was quantitated by Image J analysis after IHC. * indicates significant difference between IR treatment and Sham within the same sex ($P \leq 0.05$), as determined by 1-way ANOVA with Newman Keuls *post-hoc* test; Φ indicates significant difference between sexes in the same time point same treatment ($P \leq 0.05$), as determined by unpaired t-test; τ indicates significant difference between same sex IR compared to WT IR ($P \leq 0.05$), as determined by 1-way ANOVA with Newman Keuls *post-hoc* test.

serum IgM (**Figure 5A**), it is likely that with over 6000 ng/ml, sufficient IgM was available to activate complement. Complement activation leads to series of proteolytic amplifying events, including the cleavage of C3 and C5, which are common to all three-initiation pathways. Cleavage of each component results in deposition of C3b or C5b respectively on the tissue. As demonstrated in **Figure 3** and **Supplementary Figure 2**, wildtype, C57B6L/mice had significantly more C3b deposited on intestinal tissue in male mice than female mice. Importantly 2-way ANOVA indicated a significant difference based on sex but not on strain or the interaction of sex with the strains. Although not significant at 1 hr post ischemia, measurement of C3b deposition on intestinal tissue in complement deficient male mice was slightly decreased compared to staining of wildtype tissue. Thus, it appears that the multiple initiation pathways can compensate for the deletion of C1q, MBL or properdin in male mice. In contrast, the reduction of C3b in female mice after 1 hr reperfusion was not significantly different from Sham treated animals in either wildtype or complement deficient mice.

Similar to C3 cleavage, C5 cleavage generates an anaphylatoxin, C5a that is critical for initiation of neutrophil recruitment and activation and instigates increased IR-induced tissue damage (50–52). Thus, we examined C5a levels in the blood. C5a was the only analyte that differed significantly between sexes in Sham treated animals (**Supplementary Table 1**). Therefore, Sham treatments were not pooled for C5a. **Figure 5C** demonstrates that Sham-treated, male C1q^{-/-} mice produced significantly more C5a compared to corresponding male Sham-treated mice. In response to IR, serum C5a increased in both sexes of WT and female C1q^{-/-} mice. In contrast, C5a

concentrations in IR-treated MBL^{-/-} or P^{-/-} mice decreased or remained similar to Sham treatment (**Figure 5C**). Importantly, after IR, the serum C5a in females was consistently significantly lower when compared to males from the same strain. Although there was no significant difference in the interaction of sex with the strains, 2-way ANOVA indicated significant differences between both sexes and strains. Taken together, our data suggest that 1) generally, females express less C5a in response to Sham or IR treatment than males, 2) deletion of MBL or properdin decreases serum C5a levels in both sexes after IR and 3) deletion of C1q does not change serum C5a.

Complement Deficiency Decreases Intestinal Inflammatory Secretions in a Sex Dependent Manner

Previous studies showed that eicosanoids, LTB₄ and PGE₂ are rapidly elevated in response to intestinal IR (53, 54). To confirm the role of C1q, MBL, and properdin in the inflammatory response to mesenteric IR, we examined *ex vivo* generation of both eicosanoids in intestine tissues after IR in all deficient mice. Similar to previous studies (24), intestines from IR treated WT female mice generated significantly elevated LTB₄ at 120 min reperfusion, while LTB₄ production was not increased in WT male mice when compared to male Sham treated mice (**Figure 6A**). Deletion of C1q or MBL, in male mice significantly increased the production of LTB₄ to similar levels as found in female mice (**Figure 6A**). In contrast, IR-treated intestines from P^{-/-} male or female mice produced LTB₄ similar to Sham treatment (**Figure 6A**). The interaction of sex with strains as




FIGURE 6 | Complement deficiency decreases intestinal inflammatory secretions in a sex dependent manner. Male (blue) and female (yellow) C57B6/J WT, C1q^{-/-}, MBL^{-/-}, and P^{-/-} mice were subjected to Sham (pooled from all strains) or IR treatment with 120 min reperfusion. Intestinal sections were analyzed *ex vivo* for (A) LTB₄, (B) PGE₂, (C) MCP-1, (D) TNF-α, (E) IL-12p40 and (F) IL-10 production and standardized to mg total tissue protein. * indicates significant difference between IR treatment and Sham within the same sex (P ≤ 0.05), as determined by 1-way ANOVA followed by Newman Keuls *post-hoc* test; Φ indicates significant difference between sexes in the same time point same treatment (P ≤ 0.05), as determined by unpaired t-test; τ indicates significant difference between same sex compared to WT IR (P ≤ 0.05), as determined by 1-way ANOVA with Newman Keuls *post-hoc* test. Each bar is representative of 3-7 mice per group.

well as both sex and strains differed significantly as determined by 2-way ANOVA.

Similar to our previous studies (24), intestines from IR treated WT male mice generated significantly elevated PGE₂ at 120 min post-ischemia, while WT female mice maintained low PGE₂ production similar to Sham-treated mice and significantly lower than male mice (**Figure 6B**). Deletion of C1q, MBL, or properdin in male mice significantly reduced production of PGE₂ (**Figure 6B**). However, there was minimal change in the PGE₂ production in female MBL^{-/-} or P^{-/-} mice compared to the corresponding WT mice (**Figure 6B**). Although increased in response to IR in C1q^{-/-} females, PGE₂ production remained less than half of the quantity produced by intestines from WT male mice (**Figure 6B**). Similar to LTB₄, 2-way ANOVA indicated that the interaction of sex and strains differed significantly.

Intestinal ischemia/reperfusion induces TLR4 and subsequent pro-inflammatory cytokines that alter the inflammatory cellular response as well (22, 55). Intestines from WT male mice produced significantly increased MCP-1 (CCL2) and TNF-α which was not produced by intestines from WT females or any complement deficient mice (**Figures 6C, D**). In contrast, intestines from females of any strain of Sham treated mice produced significant quantities of IL-12p40 that was significantly decreased with IR. Importantly, IL-12p40 production by IR treated intestines from male WT mice was significantly increased compared to Sham treatment and was comparable to Sham-treated females. Mice of either sex with deficiency in complement components, C1q, MBL or P, reduced IL-12p40 production after IR. *Ex vivo* intestinal IL-10 production was also elevated in females after Sham treatment with no increased in response to IR in wildtype or complement deficiency. In contrast, male IL-10 expression increased in

response to IR in WT and was significantly elevated in C1q^{-/-} mice but not in MBL^{-/-} or P^{-/-} mice. While the specific cytokine response differed by sex and by strain of mice, the interaction of sex with the mouse strain was significantly different in each cytokine. In addition, 2-way ANOVA indicated that sex was not significantly different in intestinal IL-12p40 and IL-10 secretion.

These results suggest that complement is critical for inducing intestinal tissue inflammation damage during IR for both sexes. All three complement initiation pathways are critical for IR-induced injury in male mice. In contrast, complement activation appears lower or delayed in female mice and is primarily initiated *via* the MBL pathway. Amplification of the complement cascade by the alternative pathway is required in both sexes. This decrease in complement activation in females is accompanied by an increase in LTB₄ and anti-inflammatory cytokines under Sham conditions.

DISCUSSION

Complement activation is critical in mesenteric IR and other forms of IR-induced injury and inflammation (35, 44, 45, 56–58). Previous studies showed that intestinal, renal, and myocardial IR induced tissue damage are largely dependent on complement activation (4, 37, 50, 59, 60). Interestingly, in response to IR, the alternative complement pathway causes significant renal damage whereas intestinal and myocardial injury are more dependent on classical and MBL pathways (59). Although it is well established that IR-induced damage involves complement, the mechanistic differences between the sexes are not well understood. In humans and in other models of complement activation, complement activations appears to differ by sex (45, 61). Most IR studies used

male mice as females are smaller and have less C6 and C9 activity *in vitro* (45). However, it was unknown if complement initiation in response to IR differ between sexes *in vivo*. We hypothesized that in C57B6L/mice, females may initiate complement by a different pathway than males. This study expands our previous study (24), demonstrating a sex dimorphism in the response of wildtype C57B6L/mice to intestinal IR-induced complement activation and the mechanisms were clarified in C1q^{-/-}, and MBL^{-/-} mice. Our data demonstrate that although both sexes activate complement, females appear dependent on MBL initiation while males use C1q and MBL to initiate complement. While both male and female WT mice have significantly increased intestinal damage after IR, differences between sexes were apparent at multiple levels. In response to IR, intestinal transcription of *C1qa* gene and *MBL-C* genes were significantly different with significantly increased C1q in male and increased *MBL-C* in female mice, respectively (**Figures 1A, B**). During the same time points, FB gene maintained a similar transcription level in both sexes (**Figure 1C**). In contrast, at the protein level, both male and female mice increased intestinal staining of complement initiators, C1q and MBL-C in response to IR (**Figure 2**). However, deposition of both C1q and MBL were increased in males compared to females after IR while FB was similar (**Figure 2**). Thus, although previous studies agree that complement activation is critical during intestinal IR (7, 62, 63), the specific complement initiators utilized demonstrated a sex bias.

Many complement components are expressed by extrahepatic tissues including MBL-C and C1q (29, 31, 64, 65). While MBL-A, MBL-C and C1q are produced by the liver and found in the sera, intestinal epithelial and Paneth cells also produce MBL-C and C1q (29, 31, 64, 65). Thus, the current studies do not indicate the specific cell type producing the complement components. In addition, MBL-A is primarily produced by the liver as an acute phase protein, but it is only slightly elevated at eight hours post lipopolysaccharide treatment (28). Importantly, intestinal cells do not appear to produce MBL-A (29). Based on this information and our preliminary data demonstrating a lack of MBL-A, this study focused on MBL-C within the intestine. Future studies may examine the reperfusion time frame of MBL-A deposition within the intestine.

C1q recognition of antibody-antigen complexes initiates the classical pathway and MBL recognition of carbohydrate patterns triggers the MBL pathway (66, 67). A recent study shows that IgM forms complement-activating complexes with C1q on cell membranes similar to IgG1-C1 to mediate complement activation (68). Additional studies demonstrate that MBL may also recognize carbohydrate structures on the IgM (3, 69, 70). To address whether C1q and MBL play different roles in IR induced injury in different sexes, C57B6L/mice and mice genetically deficient in early components of either C1q-dependent classical or MBL pathways were characterized in intestinal model of IR damage. Male mice showed significantly lower tissue injury in absence of C1q or MBL, while females showed significantly lower damage in absence of MBL, but not C1q, at least under the conditions of our model. Previous studies show disagreement on

whether mice deficient in C1q protected in distinct IR models (35, 57). The Classical pathway was robustly activated during heart and kidney ischemia (35, 57) and C1q deficiency protected animals from cerebral IR injury (71, 72). However, male C1q deficiency did not protect in 20-40 min ischemia, followed by 3 hr reperfusion in either the intestinal (3, 7) or myocardial injuries (73). In contrast, our data demonstrate that intestines from C1q^{-/-} males are protected from 30 min intestinal ischemia, followed by 2 hr reperfusion. Although female C1q^{-/-} mice sustained some injury and statistically were not protected from IR-induced injury, when compared to wildtype female mice, all female mice were significantly protected compared to male C57B6L/mice. The difference between Hart et al. (3, 7) may be attributed to distinct reperfusion times or a different background strain. On the other hand, Zhang et al. (3, 7) did not specify animal sex but had 4 animals with significant injury and 2 without injury, suggesting a possible sexual dichotomy.

In contrast to the C1q studies, our studies with MBL^{-/-} mice are consistent with the previous studies (3, 7). Previous studies documented that MBL-deficient male mice were protected in renal (33), intestinal (3, 7), and myocardial (73) IR injuries. Similarly, we demonstrated that the absence of MBL in both male and female mice sustained significantly less tissue damage. The sexual dichotomy within complement activation is not new, as Kotimaa et al. (45) demonstrated different C6 and C9 activity in males and females despite similar C3 activation. However, our data is the first to report that the absence of MBL protects female mice. It is important to note that a lack of properdin had an intermediate effect on IR-induced intestinal injury. This may be explained by the redundancy of the complement pathways and the amplification of the alternative pathway. Together, these data suggest that male and female C57B6L/mice utilize distinct complement pathways.

The role of C5a in intestinal ischemia reperfusion injury is well established in male mice with early data suggesting that C5a is active in recruiting the inflammatory infiltrate (53, 74–76). A recent study demonstrated a role for C5a receptors 1 and 2 in activating and regulating neutrophilic infiltration in response to IR (52). Interestingly, their study demonstrated plasma C5a in male C57B6L/mice increased within 30 mins post-ischemia but was significantly decreased by 150 min post-reperfusion. However, in the current study, serum C5a increased in C57B6L/mice at 120 min post-reperfusion. These differences are likely due to differences in samples (plasma vs serum) as well as collecting the sample at room temperature and in the absence of the serine protease inhibitor nafamostat mesylate (52). These collection differences also appear to result in additional C5a activation with an increase in C5a concentrations. While these are significant differences, the male and female samples in this study were treated similarly and males produced significantly more serum C5a than females. Together, these studies suggest that while it is optimal to evaluate C5a in plasma with a serine protease inhibitor, sera C5a levels differ by sex.

The establishment of the crucial roles of complement initiation pathways in intestinal IR injury in each sex does not exclude the involvement of other innate immune component. Previous studies indicated that intestinal IR resulted in TLR4 and

TLR2 induction of both PGE₂ and pro-inflammatory cytokines in male mice (22, 23). Additional recent studies demonstrate IR induces injury *via* TLR4 and subsequent signaling of MyD88 and NF- κ B (55). While the authors demonstrate that dexmedetomidine inhibits IR-induced injury, they do not identify the sex of the animals (55). The current study also found increased PGE₂, MCP-1 and TNF- α produced *ex vivo* by the male ischemic intestine and these secretions were severely reduced in the absence of any complement initiating factor. This is similar to the TLR deficient mice suggesting that TLR and complement initiation cross-talk to induce cytokine production (22, 23). Crosstalk between the two pathways was demonstrated to involve HMGB-1 and phosphoinositol-3-kinase in male mice (77). In contrast, female mice produced the neutrophil chemotactic, LTB₄ and increased IL-10 and IL-12p40 in wildtype mice. Importantly, the lack of C1q or MBL did not significantly decrease the production of these secretions. Thus, the mechanism of TLRs in crosstalk with complement activation may differ in female mice subjected to intestinal IR. It is possible that the sexes may differ in the use of STING (stimulator of interferon genes) as a trigger of lipid peroxidation in intestinal IR. Although, the animal sex was not identified, STING appears to be critical in production of IR-induced eicosanoids, *via* Cox-2 and ALox, as well as cytokines (78, 79). These data are supported by the increase in IL-10 and IL-12p40 but not IL-12p35 in a sepsis model of LPS and C5a (80). Importantly, the TLR and complement crosstalk was not mediated by PI3K when using female mice (80). Together, these data suggest that signaling within male and female cells may differ.

In conclusion, we demonstrated that C1q-deficient male mice, but not females, were protected from intestinal IR injury at 2 hr post ischemia. In contrast MBL-deficiency protect both male and female mice in the mesenteric model. Future studies are needed to focus on MBL specific inhibitors which would protect both sexes from intestinal IR. This study also provides *in vivo* evidence that in response to intestinal IR males and females initiate distinct complement pathways and secretions leading to distinct patterns of injury. Other forms of IR (myocardial, renal or cerebral) should examine the specific differences used by each sex. Sex must be considered as an important factor in future mouse and clinical IR studies and likely for most studies.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

REFERENCES

1. Eror AT, Stojadinovic A, Starnes BW, Makrides SC, Tsokos GC, Shea-Donohue T. Antiinflammatory effects of soluble complement receptor type 1 promote rapid recovery of ischemia/reperfusion injury in rat small intestine. *Clin Immunol* (1999) 90(2):266–75. doi: 10.1006/clim.1998.4635

ETHICS STATEMENT

The animal study was reviewed and approved by Kansas State University Institutional Animal Care and Use Committee.

AUTHOR CONTRIBUTIONS

MW, JR, and SF performed the experiments, analyzed data, and wrote the manuscript and critically reviewed the manuscript. MW and SF designed experiments and directed animal experiments. SF was responsible for conception of the study and supervising the work. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Defense Medical Research and Development Program under Award No. W81XWH-18-1-0716. Additional support was obtained from National Institutes of Health P20GM103418, the H.L. Snyder Medical Research Foundation and the Johnson Cancer Research Center at Kansas State University. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense or National Institutes of Health.

ACKNOWLEDGMENTS

The properdin deficient mice were graciously provided by Dr. Wenchao Song, University of Pennsylvania with grant support from NIH RO1 AI085596. We also acknowledge Donald Harbridge and Joel Sanneman for assistance with the Molecular Biology Core and cryostat usage in the Confocal Core, respectively. Both the Molecular Biology Core and the Confocal Core are supported by CVM-KSU.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2021.649882/full#supplementary-material>

2. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. *Ann Thorac Surg* (1999) 68(5):1905–12. doi: 10.1016/S0003-4975(99)01073-5
3. Hart ML, Ceonzo KA, Shaffer LA, Takahashi K, Rother RP, Reenstra WR, et al. Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. *J Immunol* (2005) 174(10):6373–80. doi: 10.4049/jimmunol.174.10.6373

4. Wang W, Tang T, Zhang P, Bu H. Postconditioning attenuates renal ischemia-reperfusion injury by preventing DAF down-regulation. *J Urol* (2010) 183(6):2424–31. doi: 10.1016/j.juro.2010.01.066
5. Siegel C, Turtzo C, McCullough LD. Sex differences in cerebral ischemia: possible molecular mechanisms. *J Neurosci Res* (2010) 88(13):2765–74. doi: 10.1002/jnr.22406
6. Lock G. Acute intestinal ischaemia. *Best Pract Res Clin Gastroenterol* (2001) 15(1):83–98. doi: 10.1053/bega.2000.0157
7. Zhang M, Takahashi K, Alicot EM, Vorup-Jensen T, Kessler B, Thiel S, et al. Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. *J Immunol* (2006) 177(7):4727–34. doi: 10.4049/jimmunol.177.7.4727
8. Kawasaki T, Chaudry IH. The effects of estrogen on various organs: therapeutic approach for sepsis, trauma, and reperfusion injury. Part 1: central nervous system, lung, and heart. *J Anesth* (2012) 26(6):883–91. doi: 10.1007/s00540-012-1425-3
9. Li JL, Ao LH, Zhai YF, Cleveland JC, Fullerton DA, Meng XZ. Gender disparity in the role of TLR2 in post-ischemic myocardial inflammation and injury. *Int J Clin Exp Med* (2015) 8(7):10537–47.
10. Kahlke V, Dohm C, Brotzmann K, Schreiber S, Schroder J. Gender-related therapy: early IL-10 administration after hemorrhage restores immune function in males but not in females. *Shock* (2000) 14(3):354–9; discussion 9–60. doi: 10.1097/00024382-200014030-00020
11. Ba ZF, Shimizu T, Szalay L, Bland KI, Chaudry IH. Gender differences in small intestinal perfusion following trauma hemorrhage: the role of endothelin-1. *Am J Physiol Gastrointest Liver Physiol* (2005) 288(5):G860–5. doi: 10.1152/ajpgi.00437.2004
12. Ostadal B, Netuka I, Maly J, Besik J, Ostadalova I. Gender differences in cardiac ischemic injury and protection—experimental aspects. *Exp Biol Med (Maywood)* (2009) 234(9):1011–9. doi: 10.3181/0812-MR-362
13. Kaidonis G, Rao AN, Ouyang YB, Stary CM. Elucidating sex differences in response to cerebral ischemia: immunoregulatory mechanisms and the role of microRNAs. *Prog Neurobiol* (2019) 176:73–85. doi: 10.1016/j.pneurobio.2018.08.001
14. Park SM, Merz CNB. Women and Ischemic Heart Disease: Recognition, Diagnosis and Management. *Korean Circ J* (2016) 46(4):433–42. doi: 10.4070/kcj.2016.46.4.433
15. Choleris E, Galea LAM, Sohrabji F, Frick KM. Sex differences in the brain: Implications for behavioral and biomedical research. *Neurosci Biobehav Rev* (2018) 85:126–45. doi: 10.1016/j.neubiorev.2017.07.005
16. Persky RW, Turtzo LC, McCullough LD. Stroke in women: disparities and outcomes. *Curr Cardiol Rep* (2010) 12(1):6–13. doi: 10.1007/s11886-009-0080-2
17. Stone G, Choi A, Meritxell O, Gorham J, Heydarpour M, Seidman CE, et al. Sex differences in gene expression in response to ischemia in the human left ventricular myocardium. *Hum Mol Genet* (2019) 28(10):1682–93. doi: 10.1093/hmg/ddz014
18. Doucet D, Badami C, Palange D, Bonitz RP, Lu Q, Xu DZ, et al. Estrogen Receptor Hormone Agonists Limit Trauma Hemorrhage Shock-Induced Gut and Lung Injury in Rats. *PLoS One* (2010) 5(2):e9421. doi: 10.1371/journal.pone.0009421
19. Breithaupt-Faloppa AC, Fantozzi ET, Ramos MMD, Vitoletti LB, Couto GK, Lino-dos-Santos-Franco A, et al. Protective Effect of Estradiol on Acute Lung Inflammation Induced by an Intestinal Ischemic Insult is Dependent on Nitric Oxide (vol 40, pg 203, 2013). *Shock* (2013) 40(5):439–. doi: 10.1097/01.shk.0000436775.19120.8d
20. Breithaupt-Faloppa AC, Fantozzi ET, Romero DC, Rodrigues AD, de Sousa PTR, Franco ALD, et al. Acute Effects of Estradiol on Lung Inflammation Due to Intestinal Ischemic Insult in Male Rats. *Shock* (2014) 41(3):208–13. doi: 10.1097/SHK.0000000000000092
21. Mangino MJ, Murphy MK, Anderson CB. Effects of the arachidonate 5-lipoxygenase synthesis inhibitor A-64077 in intestinal ischemia-reperfusion injury. *J Pharmacol Exp Ther* (1994) 269(1):75–81.
22. Moses T, Wagner L, Fleming SD. TLR4-mediated Cox-2 expression increases intestinal ischemia/reperfusion-induced damage. *J Leukoc Biol* (2009) 86(4):971–80. doi: 10.1189/jlb.0708396
23. Pope MR, Fleming SD. TLR2 modulates antibodies required for intestinal ischemia/reperfusion-induced damage and inflammation. *J Immunol* (2015) 194(3):1190–8. doi: 10.4049/jimmunol.1303124
24. Wu M, Rowe JM, Fleming SD. Eicosanoid production varies by sex in mesenteric ischemia reperfusion injury. *Clin Immunol* (2020) 220:108596. doi: 10.1016/j.clim.2020.108596
25. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement System Part I - Molecular Mechanisms of Activation and Regulation. *Front Immunol* (2015) 6:262. doi: 10.3389/fimmu.2015.00262
26. Shi L, Takahashi K, Dundee J, Shahroor-Karni S, Thiel S, Jensenius JC, et al. Mannose-binding lectin-deficient mice are susceptible to infection with *Staphylococcus aureus*. *J Exp Med* (2004) 199(10):1379–90. doi: 10.1084/jem.20032207
27. Stuart LM, Takahashi K, Shi L, Savill J, Ezekowitz RA. Mannose-binding lectin-deficient mice display defective apoptotic cell clearance but no autoimmune phenotype. *J Immunol* (2005) 174(6):3220–6. doi: 10.4049/jimmunol.174.6.3220
28. Liu H, Jensen L, Hansen S, Petersen SV, Takahashi K, Ezekowitz AB, et al. Characterization and quantification of mouse mannan-binding lectins (MBL-A and MBL-C) and study of acute phase responses. *Scand J Immunol* (2001) 53(5):489–97. doi: 10.1046/j.1365-3083.2001.00908.x
29. Wagner S, Lynch NJ, Walter W, Schwaebler WJ, Loos M. Differential expression of the murine mannose-binding lectins A and C in lymphoid and nonlymphoid organs and tissues. *J Immunol* (2003) 170(3):1462–5. doi: 10.4049/jimmunol.170.3.1462
30. Choteau L, Parny M, Francois N, Bertin B, Fumery M, Dubuquoy L, et al. Role of mannose-binding lectin in intestinal homeostasis and fungal elimination. *Mucosal Immunol* (2016) 9(3):767–76. doi: 10.1038/mi.2015.100
31. Uemura K, Saka M, Nakagawa T, Kawasaki N, Thiel S, Jensenius JC, et al. L-MBP is expressed in epithelial cells of mouse small intestine. *J Immunol* (2002) 169(12):6945–50. doi: 10.4049/jimmunol.169.12.6945
32. Wu B, Ootani A, Iwakiri R, Fujise T, Tsunada S, Toda S, et al. Ischemic preconditioning attenuates ischemia-reperfusion-induced mucosal apoptosis by inhibiting the mitochondria-dependent pathway in rat small intestine. *Am J Physiol Gastrointest Liver Physiol* (2004) 286(4):G580–7. doi: 10.1152/ajpgi.00335.2003
33. Moller-Kristensen M, Wang W, Ruseva M, Thiel S, Nielsen S, Takahashi K, et al. Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. *Scand J Immunol* (2005) 61(5):426–34. doi: 10.1111/j.1365-3083.2005.01591.x
34. Mocco J, Mack WJ, Ducruet AF, Sosunov SA, Sughrue ME, Hassid BG, et al. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. *Circ Res* (2006) 99(2):209–17. doi: 10.1161/01.RES.0000232544.90675.42
35. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. *Circulation* (1998) 97(22):2259–67. doi: 10.1161/01.CIR.97.22.2259
36. Gorsuch WB, Chrysanthou E, Schwaebler WJ, Stahl GL. The complement system in ischemia-reperfusion injuries. *Immunobiology* (2012) 217(11):1026–33. doi: 10.1016/j.imbio.2012.07.024
37. Austen WG, Jr., Kyriakides C, Favuzza J, Wang Y, Kobzik L, Moore FD, Jr., et al. Intestinal ischemia-reperfusion injury is mediated by the membrane attack complex. *Surgery* (1999) 126(2):343–8. doi: 10.1016/S0039-6060(99)70175-3
38. Williams JP, Pechet TT, Weiser MR, Reid R, Kobzik L, Moore FD, Jr., et al. Intestinal reperfusion injury is mediated by IgM and complement. *J Appl Physiol* (1985) 86(3):938–42. doi: 10.1152/jappl.1999.86.3.938
39. Fleming SD, Shea-Donohue T, Guthridge JM, Kulik L, Waldschmidt TJ, Gipson MG, et al. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. *J Immunol* (2002) 169(4):2126–33. doi: 10.4049/jimmunol.169.4.2126
40. Hu C, Li L, Ding P, Li L, Ge X, Zheng L, et al. Complement Inhibitor CRIg/FH Ameliorates Renal Ischemia Reperfusion Injury via Activation of PI3K/AKT Signaling. *J Immunol* (2018) 201(12):3717–30. doi: 10.4049/jimmunol.1800987
41. Elvington A, Atkinson C, Zhu H, Yu J, Takahashi K, Stahl GL, et al. The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. *J Immunol* (2012) 189(9):4640–7. doi: 10.4049/jimmunol.1201904

42. Elvington A, Atkinson C, Kulik L, Zhu H, Yu J, Kindy MS, et al. Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. *J Immunol* (2012) 188(3):1460–8. doi: 10.4049/jimmunol.1102132
43. Haas MS, Alicot EM, Schuerpf F, Chiu I, Li J, Moore FD, et al. Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarction. *Cardiovasc Res* (2010) 87(4):618–27. doi: 10.1093/cvr/cvq141
44. Satyam A, Kannan L, Matsumoto N, Geha M, Lapchak PH, Bosse R, et al. Intracellular Activation of Complement 3 Is Responsible for Intestinal Tissue Damage during Mesenteric Ischemia. *J Immunol* (2017) 198(2):788–97. doi: 10.4049/jimmunol.1502287
45. Kotimaa J, Klar-Mohammad N, Gueler F, Schilders G, Jansen A, Rutjes H, et al. Sex matters: Systemic complement activity of female C57BL/6j and BALB/cj mice is limited by serum terminal pathway components. *Mol Immunol* (2016) 76:13–21. doi: 10.1016/j.molimm.2016.06.004
46. Giefing-Kroll C, Berger P, Lepperdinger G, Grubeck-Loebenstien B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. *Aging Cell* (2015) 14(3):309–21. doi: 10.1111/ace.12326
47. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. *Arch Surg* (1970) 101(4):478–83. doi: 10.1001/archsurg.1970.01340280030009
48. Pope MR, Bukovnik U, Tomich JM, Fleming SD. Small beta2-glycoprotein I peptides protect from intestinal ischemia reperfusion injury. *J Immunol* (2012) 189(10):5047–56. doi: 10.4049/jimmunol.1200290
49. Sjogren RW, Colleton C, Shea-Donohue T. Intestinal myoelectric response in two different models of acute enteric inflammation. *Am J Physiol* (1994) 267(3 Pt 1):G329–37. doi: 10.1152/ajpgi.1994.267.3.G329
50. Fleming SD, Mastellos D, Karpel-Massler G, Shea-Donohue T, Lambris JD, Tsokos GC. C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injury. *Clin Immunol* (2003) 108(3):263–73. doi: 10.1016/S1521-6616(03)00160-8
51. Arumugam TV, Shiels IA, Woodruff TM, Reid RC, Fairlie DP, Taylor SM. Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. *J Surg Res* (2002) 103(2):260–7. doi: 10.1006/jsre.2002.6369
52. Wu MCL, Lee JD, Ruitenberg MJ, Woodruff TM. Absence of the C5a Receptor C5aR2 Worsens Ischemic Tissue Injury by Increasing C5aR1-Mediated Neutrophil Infiltration. *J Immunol* (2020) 205(10):2834–9. doi: 10.4049/jimmunol.2000778
53. Rehrig S, Fleming SD, Anderson J, Guthridge JM, Rakstang J, McQueen CE, et al. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. *J Immunol* (2001) 167(10):5921–7. doi: 10.4049/jimmunol.167.10.5921
54. Arumugam TV, Okun E, Tang SC, Thundiyil J, Taylor SM, Woodruff TM. Toll-like receptors in ischemia-reperfusion injury. *Shock* (2009) 32(1):4–16. doi: 10.1097/SHK.0b013e318193e333
55. Yang J, Wu Y, Xu Y, Jia J, Xi W, Deng H, et al. Dexmedetomidine Resists Intestinal Ischemia-Reperfusion Injury by Inhibiting TLR4/MyD88/NF-kappaB Signaling. *J Surg Res* (2020) 260:350–8. doi: 10.1016/j.jss.2020.11.041
56. Weisman HF, Bartow T, Leppo MK, Marsh HC, Jr., Carson GR, Concino MF, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. *Science* (1990) 249(4965):146–51. doi: 10.1126/science.2371562
57. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. *J Clin Invest* (2000) 105(10):1363–71. doi: 10.1172/JCI8621
58. Tuboly E, Futakuchi M, Varga G, Erces D, Tokes T, Meszaros A, et al. C5a inhibitor protects against ischemia/reperfusion injury in rat small intestine. *Microbiol Immunol* (2016) 60(1):35–46. doi: 10.1111/1348-0421.12338
59. Morrison H, Frye J, Davis-Gorman G, Funk J, McDonagh P, Stahl G, et al. The contribution of mannose binding lectin to reperfusion injury after ischemic stroke. *Curr Neurovasc Res* (2011) 8(1):52–63. doi: 10.2174/156720211794520260
60. Miao J, Leshner AM, Miwa T, Sato S, Gullipalli D, Song WC. Tissue-specific deletion of Crry from mouse proximal tubular epithelial cells increases susceptibility to renal ischemia-reperfusion injury. *Kidney Int* (2014) 86(4):726–37. doi: 10.1038/ki.2014.103
61. Gaya da Costa M, Poppelars F, van Kooten C, Mollnes TE, Tedesco F, Wurzner R, et al. Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population. *Front Immunol* (2018) 9:2664. doi: 10.3389/fimmu.2018.02664
62. Collard CD, Vakeva A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, et al. Complement activation after oxidative stress: role of the lectin complement pathway. *Am J Pathol* (2000) 156(5):1549–56. doi: 10.1016/S0002-9440(10)65026-2
63. Collard CD, Vakeva A, Bukusoglu C, Zund G, Sperati CJ, Colgan SP, et al. Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway. *Circulation* (1997) 96(1):326–33. doi: 10.1161/01.CIR.96.1.326
64. Zhang J, Ye J, Ren Y, Zuo J, Dai W, He Y, et al. Intracellular activation of complement C3 in Paneth cells improves repair of intestinal epithelia during acute injury. *Immunotherapy* (2018) 10(15):1325–36. doi: 10.2217/imt-2018-0122
65. Ghebrehiet B, Hosszu KH, Peerschke EI. C1q as an autocrine and paracrine regulator of cellular functions. *Mol Immunol* (2017) 84:26–33. doi: 10.1016/j.molimm.2016.11.003
66. Gadjeva M, Takahashi K, Thiel S. Mannan-binding lectin—a soluble pattern recognition molecule. *Mol Immunol* (2004) 41(2-3):113–21. doi: 10.1016/j.molimm.2004.03.015
67. Roos A, Bouwman LH, Munoz J, Zuiverloon T, Faber-Krol MC, Fallaux-van den Houten FC, et al. Functional characterization of the lectin pathway of complement in human serum. *Mol Immunol* (2003) 39(11):655–68. doi: 10.1016/S0161-5890(02)00254-7
68. Sharp TH, Boyle AL, Diebold CA, Kros A, Koster AJ, Gros P. Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b. *P Natl Acad Sci USA* (2019) 116(24):11900–5. doi: 10.1073/pnas.1901841116
69. Lee H, Green DJ, Lai L, Hou YJ, Jensenius JC, Liu D, et al. Early complement factors in the local tissue immunocomplex generated during intestinal ischemia/reperfusion injury. *Mol Immunol* (2010) 47(5):972–81. doi: 10.1016/j.molimm.2009.11.022
70. McMullen ME, Hart ML, Walsh MC, Buras J, Takahashi K, Stahl GL. Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. *Immunobiology* (2006) 211(10):759–66. doi: 10.1016/j.imbio.2006.06.011
71. Ten VS, Yao J, Ratner V, Sosunov S, Fraser DA, Botto M, et al. Complement component c1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury. *J Neurosci* (2010) 30(6):2077–87. doi: 10.1523/JNEUROSCI.5249-09.2010
72. Ten VS, Sosunov SA, Mazer SP, Stark RI, Caspersen C, Sughrue ME, et al. C1q-deficiency is neuroprotective against hypoxic-ischemic brain injury in neonatal mice. *Stroke* (2005) 36(10):2244–50. doi: 10.1161/01.STR.0000182237.20807.d0
73. Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP, et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. *J Immunol* (2005) 175(1):541–6. doi: 10.4049/jimmunol.175.1.541
74. Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM. The role of the complement system in ischemia-reperfusion injury. *Shock* (2004) 21(5):401–9. doi: 10.1097/00024382-200405000-00002
75. Heller T, Hennecke M, Baumann U, Gessner JE, zu Vilsendorf AM, Baensch M, et al. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. *J Immunol* (1999) 163(2):985–94.
76. Proctor LM, Arumugam TV, Shiels I, Reid RC, Fairlie DP, Taylor SM. Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. *Br J Pharmacol* (2004) 142(4):756–64. doi: 10.1038/sj.bjp.0705819
77. Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M, Mackay CR, et al. Functional roles for C5a receptors in sepsis. *Nat Med* (2008) 14(5):551–7. doi: 10.1038/nm1753
78. Wu J, Liu Q, Zhang X, Wu X, Zhao Y, Ren J. STING-dependent induction of lipid peroxidation mediates intestinal ischemia-reperfusion injury. *Free Radic Biol Med* (2021) 163:135–40. doi: 10.1016/j.freeradbiomed.2020.12.010
79. Zhang X, Wu J, Liu Q, Li X, Li S, Chen J, et al. mtDNA-STING pathway promotes necroptosis-dependent enterocyte injury in intestinal ischemia reperfusion. *Cell Death Dis* (2020) 11(12):1050. doi: 10.1038/s41419-020-03239-6

80. Okazaki N, Hazeki K, Izumi T, Nigorikawa K, Hazeki O. C5a controls TLR-induced IL-10 and IL-12 production independent of phosphoinositide 3-kinase. *J Biochem* (2011) 149(3):265–74. doi: 10.1093/jb/mvq136

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Wu, Rowe and Fleming. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.